Bob Marcotte
Analyst · Raymond James. Please proceed
Thank you, Michael. Good morning. And thank you all for dialing in this morning. I'll cover the highlights for last quarter, and then turn to the call over to Nicole Schaltenbrand to review the details of our financial results for the period. Beginning with our last quarter results, funding's last quarter were a modest at $46 million as new deal buyout activity was building over the period. And several transactions carried over to the current quarter. We did close two new platform investments, which represented two-thirds of the originations with add-ons to our existing portfolio representing the balance. Consistent with the spike in refinancing activity for larger middle market credits, two of our larger investments in Giving Health and Pansophic were refinanced, lifting the total prepayments and amortization for the quarter to $86 million. So net originations were negative at $40 million. Short-term SOFR rates were unchanged, so the weighted average yield on our investment portfolio was largely unchanged to 13.9%. Average earning assets for the period declined slightly, resulting in a 2.2% decline in total interest income to $23.2 million for the quarter. However, other income rose to $2.5 million with an increase in prepayment fees and dividends, which lifted total investment income by $1.7 million to $25.7 million. Interest costs declined slightly on reduced line borrowings, and net management fees rose with the increased income. However, net investment income rose by $1.6 million or 15%, to $12.4 million. Net realized and unrealized gains on the portfolio totaled $6.7 million, which lifted our ROE to just under 18% for the quarter in the last 12-months. With respect to the portfolio, our portfolio continues to perform well with senior debt representing 72% of the portfolio and our three non-earning investments representing $26.4 million at cost, or $13.9 million, or 2.1% of assets of fair value. Appreciation for the quarter of $6.7 million was led by $3.3 million of realized appreciation, the unrealized appreciation of our position in ARA, which was partially offset by the depreciation of several smaller manufacturing, consumer, and service-related businesses. Regarding our near-term outlook, I'd like to leave you with a couple of comments. The majority of our investments are proprietary originations of lower middle market buyouts, often associated with a business founder transition or first institutional capital raise, and are not driven by refinancing activities. While several more mature and larger investment positions in the portfolio did take advantage of credit market conditions and lower spreads, we continue to see a healthy level of attractive lower middle market financing opportunities, typically with under $10 million of EBITDA. We entered the current quarter with a significant pipeline of awarded and high probability transactions, which we expect will support the resumption of our asset growth in the near-term. In addition to recycling some of our matured investments, we expect to continue to benefit from our incumbent position as the originator, lead lender, and in some cases, equity co-investor in a variety of smaller growth-oriented businesses as they look to grow through acquisition or expansion to support the appreciation of their equity position. We ended the quarter with a conservative leverage position at 77% of NAV and have increased the size of our bank credit facility to $269 million to support the growth of our earning assets and fee income to continue to support our shareholder distributions in the coming year. And now I'd like to turn the call over to Nicole Schaltenbrand, the CFO for Gladstone Capital to provide some more details on the fund's financial performance for the quarter. Nicole?